Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CORTNASDAQ:DRNAOTCMKTS:INVVYNASDAQ:PRNBNASDAQ:QURE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORTCorcept Therapeutics$22.66-1.5%$23.93$20.87▼$34.28$2.35B0.481.45 million shs971,180 shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AQUREuniQure$4.71+0.9%$5.39$4.61▼$22.48$225.33M0.951.00 million shs440,845 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORTCorcept Therapeutics-1.48%-4.87%-6.56%-7.21%+2.53%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%+2.08%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%QUREuniQure+0.86%-6.36%-8.19%-15.14%-75.70%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORTCorcept Therapeutics4.6989 of 5 stars3.50.00.04.53.23.33.1DRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AQUREuniQure1.8787 of 5 stars3.44.00.00.00.02.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORTCorcept Therapeutics3.00Buy$37.3064.61% UpsideDRNADicerna PharmaceuticalsN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AQUREuniQure2.71Moderate Buy$32.00579.41% UpsideCurrent Analyst RatingsLatest QURE, PRNB, CORT, INVVY, and DRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024QUREuniQureMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $7.003/1/2024QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.002/29/2024QUREuniQureThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$63.00 ➝ $8.002/16/2024CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $42.001/19/2024QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORTCorcept Therapeutics$482.38M4.86$0.93 per share24.42$4.92 per share4.61DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14QUREuniQure$15.84M14.23N/AN/A$4.34 per share1.09Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORTCorcept Therapeutics$106.14M$0.9523.8517.17N/A21.86%21.98%17.89%5/1/2024 (Estimated)DRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/APRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/AQUREuniQure-$308.48M-$6.48N/AN/AN/A-1,947.09%-99.31%-37.65%5/14/2024 (Estimated)Latest QURE, PRNB, CORT, INVVY, and DRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023QUREuniQure-$1.54-$1.53+$0.01-$1.53$3.20 million$6.69 million2/15/2024Q4 2023CORTCorcept Therapeutics$0.25$0.28+$0.03$0.28$129.27 million$135.41 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORTCorcept TherapeuticsN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORTCorcept TherapeuticsN/A4.394.31DRNADicerna PharmaceuticalsN/A2.462.46INVVYIndiviorN/AN/AN/APRNBPrincipia BiopharmaN/A17.0117.01QUREuniQure0.498.858.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORTCorcept Therapeutics93.61%DRNADicerna Pharmaceuticals78.91%INVVYIndivior0.05%PRNBPrincipia Biopharma95.54%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipCORTCorcept Therapeutics19.80%DRNADicerna Pharmaceuticals10.20%INVVYIndiviorN/APRNBPrincipia Biopharma16.01%QUREuniQure4.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCORTCorcept Therapeutics352103.52 million83.02 millionOptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableQUREuniQure48047.84 million45.90 millionOptionableQURE, PRNB, CORT, INVVY, and DRNA HeadlinesSourceHeadlineuniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - April 9 at 4:58 AMUniQure (QURE) Reports Q4 Loss, Tops Revenue Estimateszacks.com - February 28 at 9:20 AMuniQure Announces 2023 Financial Results and Highlights Recent Company Progressglobenewswire.com - February 28 at 7:05 AMuniQure: The AMT-130 Readoutseekingalpha.com - July 17 at 1:47 PMMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureseekingalpha.com - May 22 at 5:38 PMuniQure: Financials And Pipeline Signal A Promising Outlook For Investorsseekingalpha.com - May 20 at 9:19 AMWhy Sunstar's unique M&A model is attractive to independent agencies - Insurance Businessinsurancebusinessmag.com - February 7 at 2:42 PMUnique new Greenville business hoping to lather up same success of other locations - WNCTwnct.com - February 7 at 2:42 PMNew: The Buffalo Gift Emporium is Expanding its Unique Selection of Gifts - Step Out Buffalostepoutbuffalo.com - February 7 at 2:42 PMMarshall fire victims with no renter's insurance face unique obstacles - The Colorado Suncoloradosun.com - February 7 at 2:42 PM'Chess on ice:' Curling classes give Olympic viewers chance to try unique sport in Grand Rapids - MLive.commlive.com - February 7 at 2:42 PMReview: Bittersweet, quirky 'Sapience' takes unique look at the hurdles of communication - The San Diego Union-Tribunesandiegouniontribune.com - February 7 at 2:42 PMHappy Rose Day: 5 Unique Rose Recipes You Can Make For Loved Ones - NDTV Foodfood.ndtv.com - February 7 at 9:41 AMUnique partnership solves UP bridge problem | News, Sports, Jobs - Escanaba Daily Pressdailypress.net - February 7 at 9:41 AMGeneva's Little Traveler to celebrate 100 years of unique shopping experience - Shaw Localshawlocal.com - February 7 at 9:41 AMPenguins duo unveils unique NIL deal with Austintown business - Warren Tribune Chronicletribtoday.com - February 7 at 9:41 AMDozens of unique vendors set up shop for Craft Fair - Marshalltown Times Republicantimesrepublican.com - February 7 at 9:41 AMUnique math class helps students build their futures - FOX 31 Denverkdvr.com - February 7 at 9:41 AMA DoSeum experience as unique as you and me - San Antonio Reportsanantonioreport.org - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireglobenewswire.com - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Diseasefinance.yahoo.com - February 7 at 9:41 AM'Cats on Mats' gives Bloomington adoption event a unique twist - HOI ABChoiabc.com - February 6 at 8:12 AMWould You Ride...These Crazy Unique Roller Coasters? - Theme Park Touristthemeparktourist.com - February 6 at 3:12 AM'Cats on Mats' gives Bloomington adoption event a unique twist - week.comweek.com - February 6 at 3:12 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCorcept TherapeuticsNASDAQ:CORTCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Dicerna PharmaceuticalsNASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Principia BiopharmaNASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.uniQureNASDAQ:QUREuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.